No Data
JMP Securities Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $348
BeiGene's Strong Market Position and Growth Potential: A Buy Rating by Reni Benjamin
U.S. stock movement | BEIGENE (ONC.US) pre-market rose over 3% as Toripalimab was approved for a new indication in the U.S.
On Tuesday, BEIGENE (ONC.US) rose over 3% in Pre-Market Trading, priced at $253.98.
BeiGene Shares Are Trading Higher After the Company Announced FDA Approval of Tevimbra/chemotherapy Combination.
BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment
Express News | FDA Approves TEVIMBRA In US For The First-Line Treatment Of Adults With Unresectable Or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
